Temozolomide in combination with celecoxib in patients with advanced melanoma. A phase II study of the Hellenic Cooperative Onco

Primary tabs

Average: 4 (1 vote)
Therapeutic intervention: 
Therapeutic Substance(s): 
Publication type: 

Ann Oncol. 2006 Dec;17(12):1835-41.

Temozolomide in combination with celecoxib in patients with
advanced melanoma. A phase II study of the Hellenic Cooperative
Oncology Group.

Gogas H, Polyzos A, Stavrinidis I, Frangia K, Tsoutsos D, Panagiotou P, Markopoulos C, Papadopoulos O, Pectasides D, Mantzourani M, Middleton M, Vaiopoulos G, Fountzilas G.
First Department of Medicine, University of Athens, Medical School, Athens, Greece.

There is now increasing evidence that a constitutive expression of
cyclooxygenase (COX)-2 plays a role in the development and progression
of malignant epithelial tumors. Expression of COX-2 is seen in 93% of
melanomas, as determined by immunohistochemistry. Temozolomide (TMZ)
has demonstrated activity against melanoma and has been investigated as
single agent or in combination. We designed a phase II study to assess
the efficacy and toxicity of the combination of TMZ and celecoxib (a
COX-2 inhibitor) in patients with advanced melanoma.
From January 2003 to July 2004, 52 patients were enrolled in
the study. Nineteen patients were M1a, six M1b and 27 M1c. Patients
received TMZ 200 mg/m(2) per day p.o. for 5 consecutive days every 4
weeks and celecoxib 400 mg b.i.d. p.o. for a maximum of six cycles.
Celecoxib was continued until progression.
RESULTS: The median age was
63 years. There were 29 males and 23 females. Among 50 assessable
patients, there were 11 (21.5%) objective responses including five
complete responses and six partial responses. Twenty patients (38.5%)
had stabilization of their disease, and 19 (36.5%) progressed. The
median time to progression was 4.6 months and the median survival 9.5
months. Twenty-two patients (41.5%) completed all cycles of treatment.
Median relative dose intensity of TMZ was 0.99 (range 0.6-1.2). Most
commonly seen toxic effects included anemia (27.5%), neutropenia
(17.5%), thrombocytopenia (33%), nausea/vomiting (75%),
gastrointestinal (52%) and fatigue (46.5%). One patient discontinued
due to severe toxicity. COX-2 was determined by immunohistochemistry
and was expressed in all cases.
CONCLUSION: The combination of TMZ and
celecoxib is safe and potentially effective in the treatment of
metastatic melanoma. Randomized studies are needed to explore the role
of celecoxib in combination with chemotherapy or as maintenance
treatment in these patients.